Drugs / AZD4076
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02826525 | Jul 2016 → Oct 2019 | metabolic dysfunction-associated steatotic liver disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02612662 | Nov 2015 → Nov 2017 | metabolic dysfunction-associated steatohepatitis | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4076 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02826525 ↗ |
| Known as | AZD4076 tetracosasodium | “This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing...” NCT02612662 ↗ |
| Route | Subcutaneous | “Both drugs will be administered subcutaneously in the abdomen” NCT02826525 ↗ |